Article

From ASCO: Updates on the Afinitor BOLERO-3 study in breast cancer

Author(s):

Debu Tripathy

Debu Tripathy blog image

Debu Tripathy, MD, editor-in-chief of CURE, discusses the BOLERO-3 study, which combines the mTOR inhibitor, everolimus, with Herceptin (trastuzumab) and chemotherapy in patients whose cancers progressed on previous treatment. This study was presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of man.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Related Content
A new endoscopic tunneling method allowed a patient to have a GIST removed without surgery: © stock.adobe.com.
May 1st 2025

Endoscopic Procedure Removes GIST Without Surgery

Spencer Feldman
A new endoscopic tunneling method, STER, allowed a patient to have a GIST removed without surgery, allowing quicker recovery and fewer complications.
The Importance of Spotting Endometrial Cancer
March 18th 2025

The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.
Illustration of blood cells.
May 1st 2025

In Vivo CD19 CAR-T Leads to Remission in DLBCL Without Lymphodepletion

Ryan Scott
A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following novel in vivo CD19 CAR-T therapy.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
LUT014 improved rashes in patients with colorectal cancer undergoing anti-EGFR therapy: © stock.adobe.com.
May 1st 2025

BRAF Inhibitor Gel Improves Acne-Like Skin Rashes in Colorectal Cancer

Spencer Feldman
LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, according to UCLA researchers.
Image of breast.
April 30th 2025

FDA Completes Review of Hepzato Combo in HER2– Metastatic Breast Cancer

Ryan Scott
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.